Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Mark R. Hake, CFA

Heavy, Unusual Put Option Volume Today in Novo Nordisk - Is NVO Overvalued?

A Barchart report today shows unusually heavy volume in out-of-the-money (OTM) put options in Novo Nordisk (NVO), which makes Ozempic and Wegovy (for weight loss and Type 2 diabetes). NVO stock has been moving up, so is it overvalued now?

NVO is at $49.23 in midday trading on July 1, up over 2.6%. In the past 4 weeks, NVO has risen 20% from its low point on June 8 ($41.02).

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.